Trial reportJCO oncology practice2023
Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial.
Trial report in JCO oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00079066 (A Phase III Randomized Study of Cetuximab), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma
Who cites it
51 citing papers in PubMed.
- Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.The oncologist · 2023Trial
- Time toxicity among patients with cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Time Toxicity in Advanced Breast Cancer: Psychological Burden, Psychiatric Vulnerability, and Implications for Patient-Centered Decision-Making.Medicina (Kaunas, Lithuania) · 2026Review
- An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer.The oncologist · 2026Article
- Patient, care partner, and oncologist perspectives on clinically important survival thresholds after considering time toxicity in advanced cancer.The oncologist · 2026Article
- Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals.JAMA network open · 2026Article
- Withstanding the test of time for patients in oncology clinical trials.The oncologist · 2026Article
- Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.BJUI compass · 2026Article
- Planned time burden for patients participating in phase 2 cancer trials.The oncologist · 2026Article
- Accuracy of patient, care partner, and clinician health care contact day recall.The oncologist · 2026Article
- Understanding financial toxicity in cancer care through a social-ecological lens.Current opinion in oncology · 2026Review
- Article
- Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5-Fluorouracil/Levo-Leucovorin for Pancreatic Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer.JNCI cancer spectrum · 2026Article
- Time-Toxicity Indicators and Mitigation Strategies in Cancer Care: A Scoping Review.Journal of multidisciplinary healthcare · 2026Review
- Time toxicity during palliative chemotherapy for advanced malignancies: a prospective study.BMJ supportive & palliative care · 2025Observational
- Characterizing and Addressing the Financial, Time, and Administrative Burdens of Cancer and its Care.Current treatment options in oncology · 2025Review
- Measuring the Unseen Burden: Immunotherapy and Targeted Therapy Reduce Treatment-Related Time Toxicity in Incurable Malignancies.World journal of oncology · 2025Article
- Screened but Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens.JCO oncology practice · 2025Article
- Comparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study.Journal of cancer policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe time spent in pursuing treatments for advanced cancer can be substantial. We have previously proposed a pragmatic and patient-centered metric of these time costs-which we term time toxicity-as any day with physical health care system contact. This includes outpatient visits (eg, bloodwork, scans, etc), emergency department visits, and overnight stays in a health care facility. Herein, we sought to assess time toxicity in a completed randomized controlled trial (RCT).
methodsWe conducted a secondary analysis of the Canadian Cancer Trials Group CO.17 RCT that evaluated weekly cetuximab infusions versus supportive care alone in 572 patients with advanced colorectal cancer. Initial results reported a 6-week improvement in median overall survival (OS) with cetuximab (6.1
resultsIn the overall population, median time toxic days were higher in the cetuximab arm (28
conclusionThis proof-of-concept feasibility study demonstrates that measures of time toxicity can be extracted through secondary analyses of RCTs. In CO.17, despite an overall OS benefit with cetuximab, home days were statistically similar across arms. Such data can supplement traditional survival end points in RCTs. Further work should refine and validate the measure prospectively.[Media: see text].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.